Earnings Call · Q3 FY2022·2022-11-10

Q3 22EPS -14.40%·Rev n/aQ2 22EPS -14.35%·Rev n/aQ1 22EPS +2.61%·Rev n/aQ4 21EPS +8.20%·Rev n/a⚠ consensus missing

BioXcel Therapeutics, Inc. BTAI

Vimal Mehta — Chief Executive Officer

Matt Wiley — Chief Commercial Officer or Head of Commercial

Richard Steinhart — Chief Financial Officer

+29.3%1d on move date+23.8% vs SPY3d+42.3%5d+34.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more BTAI calls or request research access.

More BTAI calls Browse calls Request research access